...
首页> 外文期刊>Parasites Vectors >Identification of novel multi-stage histone deacetylase (HDAC) inhibitors that impair Schistosoma mansoni viability and egg production
【24h】

Identification of novel multi-stage histone deacetylase (HDAC) inhibitors that impair Schistosoma mansoni viability and egg production

机译:鉴定会损害曼氏血吸虫生存能力和产卵能力的新型多阶段组蛋白脱乙酰基酶(HDAC)抑制剂

获取原文
           

摘要

Abstract BackgroundNovel anti-schistosomal multi-stage drugs are needed because only a single drug, praziquantel, is available for the treatment of schistosomiasis and is poorly effective on larval and juvenile stages of the parasite. Schistosomes have a complex life-cycle and multiple developmental stages in the intermediate and definitive hosts. Acetylation and deacetylation of histones play pivotal roles in chromatin structure and in the regulation of transcription in eukaryotic cells. Histone deacetylase (HDAC) inhibitors modulate acetylation of several other proteins localized both in the nucleus and in the cytoplasm and therefore impact on many signaling networks and biological processes. Histone post-translational modifications may provide parasites with the ability to readily adapt to changes in gene expression required for their development and adaptation to the host environment. The aim of the present study was to screen a HDAC class I inhibitor library in order to identify and characterize novel multi-stage hit compounds.MethodsWe used a high-throughput assay based on the quantitation of ATP in the Schistosoma mansoni larval stage (schistosomula) and screened a library of 1500 class I HDAC inhibitors. Subsequently, a few hits were selected and further characterized by viability assays and phenotypic analyses on adult parasites by carmine red and confocal microscopy.ResultsThree compounds (SmI-124, SmI-148 and SmI-558) that had an effect on the viability of both the schistosomula larval stage and the adult worm were identified. Treatment with sub-lethal doses of SmI-148 and SmI-558 also decreased egg production. Moreover, treatment of adult parasites with SmI-148, and to a lesser extent Sm-124, was associated with histone hyperacetylation. Finally, SmI-148 and SmI-558 treatments of worm pairs caused a phenotype characterized by defects in the parasite reproductive system, with peculiar features in the ovary. In addition, SmI-558 induced oocyte- and vitelline cell-engulfment and signs of degeneration in the uterus and/or oviduct.ConclusionsWe report the screening of a small HDAC inhibitor library and the identification of three novel compounds which impair viability of the S. mansoni larval stage and adult pairs. These compounds are useful tools for studying deacetylase activity during parasite development and for interfering with egg production. Characterization of their specificity for selected S. mansoni versus human HDAC could provide insights that can be used in?optimization and compound design.
机译:摘要背景新型抗血吸虫病的多阶段药物之所以需要,是因为只有一种药物吡喹酮可用于治疗血吸虫病,并且对寄生虫的幼虫和幼年期效果不佳。在中等和确定的宿主中,血吸虫具有复杂的生命周期和多个发育阶段。组蛋白的乙酰化和脱乙酰化在染色质结构和真核细胞转录调节中起关键作用。组蛋白脱乙酰基酶(HDAC)抑制剂可调节位于细胞核和细胞质中的其他几种蛋白质的乙酰化作用,因此会影响许多信号网络和生物学过程。组蛋白翻译后修饰可以使寄生虫具有适应其发育和适应宿主环境所需的基因表达变化的能力。本研究的目的是筛选HDAC I类抑制剂库,以鉴定和表征新型的多阶段命中化合物。方法我们使用了基于曼氏血吸虫幼虫阶段(schistosomula)ATP定量的高通量检测方法并筛选了1500种I类HDAC抑制剂文库。随后,选择了一些命中样品,并通过胭脂红和共聚焦显微镜对成虫体内的寄生虫进行了活力测定和表型分析,进一步表征了结果。三种化合物(SmI-124,SmI-148和SmI-558)对两者的生存力都有影响确定了血吸虫的幼虫阶段和成虫。亚致死剂量的SmI-148和SmI-558处理也降低了产蛋量。此外,用SmI-148和较小程度的Sm-124治疗成人寄生虫与组蛋白超乙酰化有关。最后,蠕虫对的SmI-148和SmI-558处理导致了一个表型,该表型的特征是寄生虫的生殖系统存在缺陷,在卵巢中具有独特的特征。此外,SmI-558诱导了卵母细胞和卵黄细胞的吞噬以及子宫和/或输卵管中的变性迹象。曼氏幼虫阶段和成年对。这些化合物是研究寄生虫发育过程中脱乙酰酶活性和干扰卵子生产的有用工具。表征曼氏沙门氏菌与人类HDAC的特异性可以提供可用于优化和化合物设计的见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号